SCHEMBL9565835

SCHEMBL9565835

CCN1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.66
LMNA P02545 1/20 0.66
ALDH1A1 P00352 1/20 0.64
PLA2G1B P04054 1/20 0.64
RAB9A P51151 1/20 0.64
ATG4B Q9Y4P1 1/20 0.64
DRD2 P14416 5/20 0.58
DRD3 P35462 4/20 0.58
CHRNA7 P36544 1/20 0.58
DRD4 P21917 3/20 0.55
HTR1A P08908 2/20 0.55
ADRA1B P35368 1/20 0.55
CHRM5 P08912 1/20 0.53
CHRM1 P11229 1/20 0.53
CHRM3 P20309 1/20 0.53
ADRB1 P08588 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2785894 0.87 DRD2 (0.77) DRD2DRD3DRD4ADRB1
SCHEMBL2783299 0.86 DRD2 (0.56) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL2784889 0.84 DRD2 (0.55) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL2782686 0.84 DRD2 (0.55) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL2784856 0.84 DRD2 (0.55) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL28396664 0.83 ADRB1 (0.71) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL844998 0.82 DRD2 (0.52) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL845243 0.82 DRD2 (0.52) KDM4ELMNAALDH1A1PLA2G1BRAB9A
SCHEMBL12126914 0.81 GAA (0.58) LMNAALDH1A1DRD2DRD3CHRNA7
SCHEMBL2782876 0.81 DRD2 (0.51) KDM4ELMNAALDH1A1PLA2G1BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-2445502-B2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS ALKERMES PHARMA IRELAND LTD (IE) 2022-09-28 EP disclosed
US-20210332046-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 US disclosed
US-11155551-B2 Nicotinic acetylcholine receptor silent agonists UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2021-10-26 US disclosed
US-20200247804-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2020-08-06 US disclosed
US-10662191-B2 Nicotinic acetylcholine receptor silent agonists UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) 2020-05-26 US disclosed
US-20180298002-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2018-10-18 US disclosed
WO-2018089493-A1 PYRROLE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2017066558-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2017-04-20 WO disclosed
US-7915405-B2 2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives for therapeutic agent of antiinflammatory disease, method thereof for preparation, therapeutic agent for antiinflammatory disease induced by SPC activity containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-03-29 US disclosed
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2010-10-21 US disclosed
US-20100145043-A1 2,4-Disubstituted-5-Aminocarbonyl-1,3-Thiazole Derivatives For Therapeutic Agent Of Antiinflammatory Disease, Method Thereof For Preparation, Therapeutic Agent For Antiinflammatory Disease Induced By SPC Activity Containing The Same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-10 US disclosed
US-7642267-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2010-01-05 US disclosed
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2008-09-18 US disclosed
US-7300945-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2007-11-27 US disclosed
US-7166572-B1 Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2007-01-23 US disclosed
US-7166572-B1 Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2007-01-23 US disclosed
EP-0548798-A1 Antiviral agent SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1993-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives GABBR1, GABBR2, GABRA2 KDM4E 1996/4885LMNA 2796/4885ALDH1A1 470/4885
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives GABBR1, GABBR2, GABRA2 KDM4E 1996/4885LMNA 2796/4885ALDH1A1 470/4885
US-20100145043-A1 2,4-Disubstituted-5-Aminocarbonyl-1,3-Thiazole Derivatives For Therapeutic Agent Of Antiinflammatory Disease, Method Thereof For Preparation, Therapeutic Agent For Antiinflammatory Disease Induced By SPC Activity Containing The Same HRH4, TSLP, IL1R1 KDM4E 2666/4885LMNA 4063/4885ALDH1A1 965/4885
US-20180298002-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS CHRNA7, CHRNA2, CHRNE KDM4E 2070/4885LMNA 3623/4885ALDH1A1 3068/4885
US-11155551-B2 Nicotinic acetylcholine receptor silent agonists CHRNA7, CHRNA2, CHRNE KDM4E 2070/4885LMNA 3623/4885ALDH1A1 3068/4885
US-10662191-B2 Nicotinic acetylcholine receptor silent agonists CHRNA7, CHRNA2, CHRNE KDM4E 2070/4885LMNA 3623/4885ALDH1A1 3068/4885
US-20200247804-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS CHRNA7, CHRNA2, CHRNE KDM4E 2070/4885LMNA 3623/4885ALDH1A1 3068/4885
US-20210332046-A1 NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS CHRNA7, CHRNA2, CHRNE KDM4E 2070/4885LMNA 3623/4885ALDH1A1 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.